Truist Securities Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has initiated coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and a price target of $10.
September 19, 2023 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Praxis Precision Medicine has been initiated with a Buy rating by Truist Securities, with a price target of $10.
The initiation of coverage by Truist Securities with a Buy rating and a price target of $10 indicates a positive outlook for Praxis Precision Medicine. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100